PCSK9 and coronary artery disorder: Drug target-disease pairs supported by human genetics have a greater odds of success in drug discovery pipelines.4 For example, identification of variants in PCSK9 associated with lower risk of coronary disease led to the successful development of PCSK9 inhibitors, which are now licensed for prevention of cardiovascular events.5 The value of human genetics for drug discovery and development has also been realized for infectious diseases.